A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
- University Medical Center of Southern Nevada — Las Vegas, Nevada
- Sunrise Hospital and Medical Center — Las Vegas, Nevada
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
- Summerlin Hospital Medical Center — Las Vegas, Nevada
- Renown Regional Medical Center — Reno, Nevada